Drugs / low molecular weight heparin calcium
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04778917 | Dec 2014 → Jul 2017 | pneumonia | Capital Institute of Pediatrics, China | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT02414802 Background | Dec 2014 → Dec 2017 | venous thromboembolism | Xuzhou Medical University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | low-molecular-weight heparin calcium | “Group B with prevention of DIC amount: low molecular weight heparin calcium 50-100 units / kg, once or twice subcutaneous injection, 5-10 days of treatment or D-Dimer recovery normal.” NCT04778917 ↗ |
| Route | Subcutaneous | “administered via subcutaneous injection of low-molecular-weight heparin calcium” NCT02414802 ↗ |